MARCIA FAVALI: Open Payments
NPI 1154437382 · TERRE HAUTE, IN. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,770 in 64 payments from 17 companies in 2025. Trend: 2023 $1,272 · 2024 $1,078 · 2025 $1,770
Food & beverage: $1,770
| Company | Payments | Amount |
|---|---|---|
| Novo Nordisk Inc | 13 | $551 |
| ABBVIE INC. | 15 | $298 |
| Lilly USA, LLC | 5 | $187 |
| Amgen Inc. | 6 | $180 |
| Alexion Pharmaceuticals, Inc. | 1 | $125 |
| GlaxoSmithKline, LLC. | 4 | $66 |
| Otsuka America Pharmaceutical, Inc. | 3 | $64 |
| Bayer Healthcare Pharmaceuticals Inc. | 3 | $54 |
| Abbott Laboratories | 2 | $41 |
| Exact Sciences Corporation | 2 | $39 |
Products named: Wegovy, Ozempic, REPATHA, ZEPBOUND, UBRELVY, QULIPTA, VRAYLAR, REXULTI.
Industry payments across IN — which companies pay providers there.
